AnnularBio

THE CONCEPT

AnnularBio was developed when its Founders recognized the market demand for reliability in contract manufacturing of high quality monoclonal antibodies (mAbs). Through their collective experiences in the biotechnology industry, specifically  commercial R&D reagents, they observed the negative consequences that questionable mAbs have on institutional researchers.

Challenging the complacency of the commercial mAb market, they desired to provide innovative and intelligent solutions for researchers that require functional mAbs. Today, AnnularBio has not only developed a methodology for selecting high-value hybridomas but they have an accelerated success rate for Clients with their discovery process.

ABitope KITS

AnnularBio offers improvements in the discovery of high-value hybridomas that ultimately provide mAbs of greater market value. This process results in panels of mAbs, otherwise known as the “ABitope Kit” with varying epitope specificities that can be exploited for numerous applications. The benefits of our technology provides the Client with a competitive edge, reducing their project time and use of valuable resources.